EAEmma Axon

Emma Axon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emma Axon has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Sensitivity Analysis in Meta‐Analysis: A Tutorial

    by Nyan Min Aung, Ivan Jurak, Seemab Mehmood, Emma Axon

    This tutorial explains when systematic review authors may consider performing a sensitivity analysis in a meta‐analysis. Such scenarios include removing studies at high risk of bias, exploring the effect of outliers and examining differences in study characteristics (e.g., participants’ age, study design). In addition, examples are provided, as well as advice on how to interpret and report the results. The tutorial also explains the differences between subgroup and sensitivity analyses, as well as describing the disadvantages of a sensitivity analysis. To support this tutorial, a link to an online module, which includes videos and quizzes, is also provided.


  • Incorporating non-randomized evidence in cochrane intervention reviews: a scoping review

    by Emma Axon, Afroditi Kanellopoulou, Sofia Tsokani, Nuala Livingstone, Jennifer Hilgart, Rachel Richardson


  • Open Access

    Supporting self-care for eczema in the community: the Eczema Care Online research programme including two RCTs

    by Ingrid Muller, Beth Stuart, Tracey Sach, Lucy Yardley, Kate Greenwell, Taeko Becque, Paul Leighton, Laura Howells, Jane Harvey, Julie Hooper, et al.

    Background: Eczema is a common condition with significant impact on quality of life. The main cause of treatment failure is non-use of prescribed treatments because treatments are time-consuming to apply; they may sting when first applied to inflamed skin; there are concerns about the safety of some treatments; and because people often receive conflicting advice about how and when to use them. Objectives: Objectives of the present study are to: (1) explore the self-care support needs of children with eczema and their parents/carers, and young people with eczema, (2) review current best evidence about the safest and best ways to use topical corticosteroids for eczema, (3) develop theory-, evidence- and person-based online interventions to support eczema self-management in young people with eczema and parents/carers of children with eczema, (4) evaluate the clinical and cost-effectiveness of the interventions in two randomised controlled trials and (5) conduct a process evaluation and implementation planning. Design: Five qualitative studies, four systematic reviews (one qualitative) and two parallel randomised controlled trials with nested process evaluation and economic evaluation. Setting: Primary care. Participants: Children and young people aged 13–25 years with eczema, and parents/carers of children aged 0–12 years with eczema. Participants with very mild or inactive eczema were excluded. Interventions: We developed and evaluated two online behavioural interventions to support eczema management in: (1) young people and (2) parents/carers of children. Participants were not blinded to group allocation. Main outcome measures: Primary outcome measure in the randomised controlled trials was participant-reported eczema severity measured by the patient-oriented eczema measure over 24 weeks. Secondary outcomes included patient-oriented eczema measures over 52 weeks, quality of life and patient enablement. Results: Qualitative reviews and interviews provided in-depth understanding of the views, experiences and contexts within which young people and families manage eczema and identified barriers and facilitators to key behaviours. Systematic literature reviews on topical corticosteroid safety and effectiveness found no evidence of harm when topical corticosteroids were used intermittently to treat or prevent eczema flares. Our Cochrane review, which included 104 trials (8443 participants), found that potent and moderate topical corticosteroids are probably more effective than mild topical corticosteroids for treating moderate or severe eczema and that effectiveness is similar between once and twice daily use. Findings informed development of two online interventions, which were evaluated in two randomised controlled trials comparing intervention plus usual care to usual care only. Three hundred and forty parents/carers (169 usual care; 171 intervention) and 337 young people (169 usual care; 168 intervention) were randomised [mean baseline patient-oriented eczema measure 12.8 (standard deviation 5.3) and 15.2 (standard deviation 5.4), respectively]. An intention-to-treat analysis approach to the analysis was taken. Follow-up rates were: 92.4% (314/340) parents/carers and 90.2% (304/337) young people at 24 weeks. Compared with usual care over 24 weeks, eczema severity (patient-oriented eczema measure) improved in the intervention groups: adjusted mean difference −1.5 (95% confidence interval −2.5 to −0.6) for parents/carers, and −1.9 (95% confidence interval −3.0 to −0.8) for young people. Effects were sustained for 52 weeks in both groups. Enablement showed an important difference favouring the intervention group in both trials [adjusted mean difference at 24 weeks −0.7 (95% confidence interval −1.0 to −0.4) for parents/carers and −0.9 (95% confidence interval −1.3 to −0.6) for young people]. No harms were identified in either group. Economic analysis found both interventions were low cost and cost-effective with almost all analyses (with the exception of the complete-case cost–utility analysis for the parent/carer trial) estimating the interventions to be dominant (cost saving and effective). Process evaluation demonstrated that both groups found the interventions usable, relatable and trustworthy, and perceived that they helped to manage their eczema. The interventions have been redeveloped into an English and Welsh product ready for dissemination and an implementation strategy has been developed. Limitations: This research was conducted during the COVID-19 pandemic. While this did not have a major impact on our research plans or delivery, it may have had impacts (positive and negative) on people’s eczema, their eczema management and access to health care. Conclusions: Eczema Care Online is effective and acceptable to its target groups. Findings from this programme support the wide-scale implementation of the interventions, available at www.eczemacareonline.org.uk. Future work: Future work may explore how Eczema Care Online can be implemented in different settings and contexts and adapted for severe eczema. More research is also needed on the long-term safety of topical corticosteroids. Trial registration: This trial is registered as Current Controlled Trials ISRCTN79282252. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme (NIHR award ref: RP-PG-0216-20007) and is published in full in Programme Grants for Applied Research; Vol. 13, No. 3. See the NIHR Funding and Awards website for further award information.


  • Open Access

    Multiarm studies and how to handle them in a meta‐analysis: A tutorial

    by Emma Axon, Kerry Dwan, Rachel Richardson

    This tutorial focuses on multiarm studies. We will explain what multiarm studies are and how to include data from them in a meta‐analysis.


  • Open Access

    Safety of topical corticosteroids in atopic eczema: an umbrella review

    by Emma Axon, Joanne R Chalmers, Miriam Santer, Matthew J Ridd, Sandra Lawton, Sinead M Langan, Douglas J C Grindlay, Ingrid Muller, Amanda Roberts, Amina Ahmed, et al.

    Objective: An umbrella review summarising all safety data from systematic reviews of topical corticosteroids (TCS) in adults and children with atopic eczema. Methods: Embase, MEDLINE, PubMed, Cochrane Database of Systematic Reviews and the Centre of Evidence Based Dermatology map of eczema systematic reviews were searched until 7 November 2018 and Epistemonikos until 2 March 2021. Reviews were included if they assessed the safety of TCS in atopic eczema and searched > 1 database using a reproducible search strategy. Review quality was assessed using version 2 of 'A MeaSurement Tool to Assess systematic Reviews' (AMSTAR 2 tool). Results: 38 systematic reviews included, 34 low/critically low quality. Treatment and follow-up were usually short (2–4 weeks). Key findings: TCS versus emollient/vehicle: No meta-analyses identified for skin-thinning. Two 2-week randomised controlled trials (RCTs) found no significant increased risk with very potent TCS (0/196 TCS vs 0/33 vehicle in children and 6/109 TCS vs 2/50 vehicle, age unknown). Biochemical adrenal suppression (cortisol) was 3.8% (95% CI 2.4% to 5.8%) in a meta-analysis of 11 uncontrolled observational studies (any potency TCS, 522 children). Effects reversed when treatment ceased. TCS versus topical calcineurin inhibitors: Meta-analysis showed higher relative risk of skin thinning with TCS (4.86, 95% CI 1.06 to 22.28, n=4128, four RCTs, including one 5-year RCT). Eight cases in 2068 participants, 7 using potent TCS. No evidence of growth suppression. Once daily versus more frequent TCS: No meta-analyses identified. No skin-thinning in one RCT (3 weeks potent TCS, n=94) or biochemical adrenal suppression in two RCTs (up to 2 weeks very potent/moderate TCS, n=129). TCS twice/week to prevent flares (‘weekend therapy’) versus vehicle: No meta-analyses identified. No evidence of skin thinning in five RCTs. One RCT found biochemical adrenal suppression (2/44 children, potent TCS). Conclusions: W e found no evidence of harm when TCS were used intermittently ‘as required’ to treat flares or ‘weekend therapy’ to prevent flares. However, long-term safety data were limited. PROSPERO registration number: CRD42018079409.


  • Letter to the editor submitted in response to “efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a Meta-analysis of randomised controlled trial”

    by Emma Axon, Douglas J. Grindlay

    Letter to the editor submitted in response to “Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a meta-analysis of randomized controlled trial.”. Journal of Dermatological Treatment. Accepted 17 August 2019.


  • Drug interventions for the treatment of obesity in children and adolescents

    by Emma Axon, Greg Atkinson, Bernd Richter, Maria-Inti Metzendorf, Louise Baur, Nicholas Finer, Eva Corpeleijn, Claire O'MAlley, Louisa J Ells

    Child and adolescent obesity has increased globally, and can be associated with significant short- and long-term health consequences. To assess the efficacy of drug interventions for the treatment of obesity in children and adolescents. We searched CENTRAL, MEDLINE, Embase, PubMed (subsets not available on Ovid), LILACS as well as the trial registers ICTRP (WHO) and ClinicalTrials.gov. Searches were undertaken from inception to March 2016. We checked references and applied no language restrictions. We selected randomised controlled trials (RCTs) of pharmacological interventions for treating obesity (licensed and unlicensed for this indication) in children and adolescents (mean age under 18 years) with or without support of family members, with a minimum of three months' pharmacological intervention and six months' follow-up from baseline. We excluded interventions that specifically dealt with the treatment of eating disorders or type 2 diabetes, or included participants with a secondary or syndromic cause of obesity. In addition, we excluded trials which included growth hormone therapies and pregnant participants. Two review authors independently assessed trial quality and extracted data following standard Cochrane methodology. Where necessary we contacted authors for additional information. We included 21 trials and identified eight ongoing trials. The included trials evaluated metformin (11 trials), sibutramine (six trials), orlistat (four trials), and one trial arm investigated the combination of metformin and fluoxetine. The ongoing trials evaluated metformin (four trials), topiramate (two trials) and exenatide (two trials). A total of 2484 people participated in the included trials, 1478 participants were randomised to drug intervention and 904 to comparator groups (91 participants took part in two cross-over trials; 11 participants not specified). Eighteen trials used a placebo in the comparator group. Two trials had a cross-over design while the remaining 19 trials were parallel RCTs. The length of the intervention period ranged from 12 weeks to 48 weeks, and the length of follow-up from baseline ranged from six months to 100 weeks. Trials generally had a low risk of bias for random sequence generation, allocation concealment and blinding (participants, personnel and assessors) for subjective and objective outcomes. We judged approximately half of the trials as having a high risk of bias in one or more domain such as selective reporting. The primary outcomes of this review were change in body mass index (BMI), change in weight and adverse events. All 21 trials measured these outcomes. The secondary outcomes were health-related quality of life (only one trial reported results showing no marked differences; very low certainty evidence), body fat distribution (measured in 18 trials), behaviour change (measured in six trials), participants' views of the intervention (not reported), morbidity associated with the intervention (measured in one orlistat trial only reporting more new gallstones following the intervention; very low certainty evidence), all-cause mortality (one suicide in the orlistat intervention group; low certainty evidence) and socioeconomic effects (not reported). Intervention versus comparator for mean difference (MD) in BMI change was -1.3 kg/m2 (95% confidence interval (CI) -1.9 to -0.8; P < 0.00001; 16 trials; 1884 participants; low certainty evidence). When split by drug type, sibutramine, metformin and orlistat all showed reductions in BMI in favour of the intervention. Intervention versus comparator for change in weight showed a MD of -3.9 kg (95% CI -5.9 to -1.9; P < 0.00001; 11 trials; 1180 participants; low certainty evidence). As with BMI, when the trials were split by drug type, sibutramine, metformin and orlistat all showed reductions in weight in favour of the intervention. Five trials reported serious adverse events: 24/878 (2.7%) participants in the intervention groups versus 8/469 (1.7%) participants in the comparator groups (risk ratio (RR) 1.43, 95% CI 0.63 to 3.25; 1347 participants; low certainty evidence). A total 52/1043 (5.0%) participants in the intervention groups versus 17/621 (2.7%) in the comparator groups discontinued the trial because of adverse events (RR 1.45, 95% CI 0.83 to 2.52; 10 trials; 1664 participants; low certainty evidence). The most common adverse events in orlistat and metformin trials were gastrointestinal (such as diarrhoea, mild abdominal pain or discomfort, fatty stools). The most frequent adverse events in sibutramine trials included tachycardia, constipation and hypertension. The single fluoxetine trial reported dry mouth and loose stools. No trial investigated drug treatment for overweight children. This systematic review is part of a series of associated Cochrane reviews on interventions for obese children and adolescents and has shown that pharmacological interventions (metformin, sibutramine, orlistat and fluoxetine) may have small effects in reduction in BMI and bodyweight in obese children and adolescents. However, many of these drugs are not licensed for the treatment of obesity in children and adolescents, or have been withdrawn. Trials were generally of low quality with many having a short or no post-intervention follow-up period and high dropout rates (overall dropout of 25%). Future research should focus on conducting trials with sufficient power and long-term follow-up, to ensure the long-term effects of any pharmacological intervention are comprehensively assessed. Adverse events should be reported in a more standardised manner specifying amongst other things the number of participants experiencing at least one adverse event. The requirement of regulatory authorities (US Food and Drug Administration and European Medicines Agency) for trials of all new medications to be used in children and adolescents should drive an increase in the number of high quality trials.